CHM Therapy Surprises Researchers

The Nuffield Laboratory of Ophthalmology  at University Oxford have reported surprising results following gene therapy clinical trials for choroideremia.In a trial set up to test the safety aspect of the therapy they were pleased and surprised to witness a calculable improvement in some of the test subjects' vision.Over the course of two years, one member of the trial saw the failure of his vision halted and apparently reversed.The question now being asked is, we have reversal of degeneration of vision at this early test stage, but how long will the effects last for?For each test subject there is a question mark over whether that particular persons cells will accept the CHM gene. It has already proved difficult for new genes to be introduced safely from previous human trial attempts.
 The eye provides a useful tool for the exploration of gene therapy as one eye can be used as a control and comparable for results. For retinal genetic research the success of this trial has many implications as it has proven that introducing gene therapy before the onset of sight loss can be accomplished.